Key Takeaways TMDX, GMED and HIMS saw strong gains driven by innovation and improved financial performance in 2025.GMED, TMDX and HIMS may face pressure in 2026 amid selective spending and valuation resets.GMED rose 3.8%, TMDX 101.4% and HIMS 32.6% over the past year, outpacing the industry's performances.In 2024 and 2025, the MedTech sector has operated against a backdrop of a global economy marked by slowing growth, moderating inflation and elevated geopolitical uncertainty. Worldwide policy shifts, persi ...